Notice: Prescription Drug List (PDL): Multiple Additions (2020-09-08)

The purpose of this Notice of Amendment is to notify about the additions of amifampridine, cedazuridine (when used in combination with another drug), etomidate, fedratinib, lefamulin, obiltoxaximab, polatuzumab vedotin, ripretinib, satralizumab and sonidegib to the Prescription Drug List (PDL) for human and/or veterinary use.

Données et ressources

Info additionnelle

Champ Valeur
Dernière modification avril 17, 2026, 21:30 (TU)
Créé le avril 17, 2026, 21:30 (TU)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2020-08-31 00:00:00
open_canada_keywords {"fr": ["avis de modification", "Liste des drogues sur ordonnance", "LPD", "usage humain et vétérinaire", "amifampridine", "cédazuridine", "étomidate", "fedratinib", "léfamuline", "obiltoxaximab", "polatuzumab vedotin", "ripretinib", "satralizumab et sonidegib"], "en": ["notice of amendment", "Prescription Drug List", "PDL", "human-and-veterinary use", "amifampridine", "cedazuridine", "etomidate", "fedratinib", "lefamulin", "obiltoxaximab", "polatuzumab vedotin", "ripretinib", "satralizumab and sonidegib"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Vitrakvi - Avis de conformité avec conditions – Avis d’admissibilité (2020-09-08)
update_frequency as_needed